Anika Therapeutics (NasdaqGS:ANIK) Q3 2025 Earnings Call November 05, 2025 08:30 AM ET Speaker2Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. I will now turn the call over to Matt Hall, Director, Corporate Development and Inves ...

Anika. Restore Active Living. SAFE HARBOR STATEMENTS Q3 2025 EARNINGS CALL NOVEMBER 5, 2025 The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meaning of Section 27A of the Securities Act of 1 ...

Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: AN ...

财务表现 - 2025年第二季度持续经营业务收入2820万美元，同比下降8%[2] - OEM渠道收入1630万美元，同比下降13%[2] - 商业渠道收入1190万美元，同比持平[2] - 毛利率51%，包含因生产良率问题产生的300万美元库存报废费用[13] - 营业费用1850万美元，同比下降17%[13] - 持续经营业务亏损460万美元，每股亏损033美元[13] - 调整后持续经营业务净亏损170万美元，每股亏损013美元[13] - 调整后EBITDA亏损20万美元[13] - 公司现金余额5320万美元[13] 再生解决方案业务 - 再生解决方案收入增长41%，主要受Integrity植入系统超预期表现和国际Hyalofast强劲增长驱动[1][3] - Integrity植入系统已超越2024年全年表现，预计2025年将实现翻倍以上增长[1] - Integrity手术量连续第五个季度增长，增速显著超越美国软组织增强市场整体水平[4] - FDA批准新增40x60mm和25x60mm规格Integrity植入物，预计年底前在美国限量推出[4] 骨关节炎疼痛管理业务 - 国际OA疼痛管理收入环比增长5%，同比下降10%，主要受2024年订单时间安排和近期生产良率问题暂时影响[5] - 美国OA疼痛管理产品定价在第二季度反弹，预计将成为全年高点[3] - 预计2025年下半年定价将出现更明显下降，2026年随着终端用户定价与市场竞争对手趋同而恢复正常[3] 产品研发与注册进展 - Hyalofast美国三期临床试验未达到预设的共同主要终点，但在预设次要终点和其他指标上显示出统计学显著改善[1][6] - 公司计划在2025年下半年提交最终PMA模块[1][6] - Cingal的NDA申报取得进展，已完成毒性研究并准备启动生物等效性研究[7] - 生产良率问题已解决，6月恢复全面生产，预计第三季度末完全消除影响[3][8] 战略调整与展望 - 维持2025年收入指引：商业渠道4700-4950万美元（增长12%-18%），OEM渠道6200-6500万美元（下降16%-20%）[12][13] - 维持2025年调整后EBITDA指引-3%至3%[12] - 因Hyalofast上市时间可能推迟，下调2026-2027年长期收入指引：商业渠道增长预期从+20%-30%调整为+10%-20%[12] - 预计Hyalofast将于2027年上市，首年销售额300万美元[12] - 已完成Arthrosurface和Parcus Medical出售相关的所有重要过渡服务[9]